The financial markets are witnessing a significant "Great Divergence" as investor sentiment pivots sharply away from the high-flying technology stocks that have dominated portfolios for years. As of December 11, 2025, a palpable shift is underway, with capital flowing out of the tech sector and into more traditional, value-oriented industries.
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more traditional value sectors and defensive equities. This ongoing recalibration reflects evolving macroeconomic conditions, a reassessment of risk appetite, and a growing
The financial markets in late 2025 present a complex narrative, a tug-of-war between the long-reigning titans of growth and a resurgent, yet often overshadowed, cohort of value stocks. While the year-to-date performance figures as of December 11, 2025, still crown growth equities as the overall victors, a closer look reveals
Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.
Pfizer reports Phase 3 results showing Tukysa with trastuzumab and pertuzumab prolonged progression-free survival by 8.6 months in HER2+ metastatic breast cancer.
As December 2025 draws to a close, financial markets are holding their breath in anticipation of a pivotal Federal Reserve interest rate decision. Investopedia's analysis reveals a pervasive market sentiment leaning heavily towards a quarter-percentage-point reduction in the federal funds rate, a move that would mark the third consecutive cut
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Tuesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Pfizer signed an exclusive global collaboration and licensing agreement with YaoPharma to develop YP05002, a small-molecule GLP-1 receptor agonist for chronic weight management.
New York, NY – December 8, 2025 – A recent report from the Federal Reserve Bank of New York (New York Fed) reveals a concerning trend: U.S. households are growing increasingly pessimistic about their financial situations, even as inflation expectations remain largely stable. Released today, the November 2025 Survey of Consumer
Free cash flow is one of the most reliable indicators of financial durability.
These businesses not only generate cash but reinvest intelligently to sustain momentum.
Shares of biotechnology company Moderna (NASDAQ:MRNA)
jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge, driven by an aging global population, the rising prevalence of chronic diseases, and relentless innovation in pharmaceutical research and development, signals
